• This update provides recommendations for perioperative treatment of locally advanced oesophageal and OGJ adenocarcinoma. • Recent phase III data have demonstrated that perioperative ChT should be the preferred approach for most patients. • Updated recommendations are also provided for the use of immune checkpoint inhibitors in advanced squamous-cell carcinoma. • Algorithms for the management of locoregional oesophageal cancer and advanced squamous-cell carcinoma are provided. • Recommendations are based on available scientific data and the authors’ collective expert opinion.

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic; Department of Comprehensive Cancer Care Faculty of Medicine Masaryk University Brno Czech Republic

The Sir Peter MacCallum Department of Oncology Peter MacCallum Cancer Centre University of Melbourne Melbourne Australia

Zobrazit více v PubMed

Obermannová R., Alsina M., Cervantes A., et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992–1004. PubMed

Reynolds J.V., Preston S.R., O’Neill B., et al. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):1015–1027. PubMed PMC

Hoeppner J., Brunner T., Schmoor C., et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med. 2025;392(4):323–335. PubMed

Leong T., Smithers B.M., Michael M., et al. Preoperative chemoradiotherapy for resectable gastric cancer. N Engl J Med. 2024;391(19):1810–1821. PubMed

Xu J., Kato K., Raymond E., et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24(5):483–495. PubMed

Wang Z.X., Cui C., Yao J., et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell. 2022;40(3):277–288. PubMed

Kato K., Cho B.C., Takahashi M., et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–1517. PubMed

Shen L., Kato K., Kim S.B., et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol. 2022;40(26):3065–3076. PubMed PMC

Ajani J., El Hajbi F., Cunningham D., et al. Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study. ESMO Open. 2024;9(1) PubMed PMC

Cherny N.I., Dafni U., Bogaerts J., et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340–2366. PubMed

Dykewicz C.A. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139–144. [adapted from: Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Clin Infect Dis. 1994;18(3):421] PubMed

Lordick F., Carneiro F., Cascinu S., et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005–1020. PubMed